恒瑞医药(600276) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥5,478,539,090.55, representing a decrease of 20.93% compared to the same period last year[2]. - The net profit attributable to shareholders was ¥1,236,949,171.02, down 17.35% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,180,040,843.66, a decline of 19.80% compared to the previous year[2]. - The basic earnings per share for the period was ¥0.19, a decrease of 17.39% compared to the same period last year[2]. - Total operating revenue for Q1 2022 was RMB 5,478,539,090.55, a decrease of 21% compared to RMB 6,929,054,893.69 in Q1 2021[14]. - Net profit for Q1 2022 was RMB 1,208,270,948.16, a decrease of 19% compared to RMB 1,496,035,486.76 in Q1 2021[16]. - Total profit for Q1 2022 was RMB 1,365,413,121.76, down 23% from RMB 1,772,760,323.18 in Q1 2021[16]. Cash Flow - The net cash flow from operating activities was ¥148,056,761.57, reflecting a decrease of 25.71% year-over-year[2]. - Cash inflow from operating activities in Q1 2022 was RMB 4,842,721,428.88, a decrease of 32% compared to RMB 7,171,334,980.17 in Q1 2021[18]. - Cash outflow from operating activities totaled ¥4,694,664,667.31, a decrease of 32.6% compared to ¥6,972,050,122.36 in the previous year[19]. - Cash inflow from investment activities amounted to ¥3,473,718,884.70, a decrease of 46.5% compared to ¥6,464,320,551.33 in the prior year[19]. - The net increase in cash and cash equivalents was ¥7,009,805.73, significantly lower than ¥1,598,389,115.45 in the same quarter last year[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥39,817,549,288.90, an increase of 1.40% from the end of the previous year[3]. - The total current assets reached RMB 30.49 billion, slightly up from RMB 30.19 billion, indicating a growth of about 1.0%[10]. - Total liabilities decreased to RMB 3.03 billion from RMB 3.69 billion, a reduction of approximately 18.0%[13]. - The equity attributable to shareholders increased to ¥36,242,720,179.44, up 3.54% from the previous year-end[3]. - The equity attributable to shareholders increased to RMB 36.24 billion from RMB 35.00 billion, reflecting a growth of about 3.5%[13]. Expenses - Total operating costs for Q1 2022 were RMB 4,157,190,134.31, down 19% from RMB 5,161,350,007.52 in Q1 2021[14]. - Research and development expenses for Q1 2022 were RMB 1,007,281,049.36, down 24% from RMB 1,316,228,078.71 in Q1 2021[16]. - Sales expenses for Q1 2022 were RMB 1,758,473,121.06, a decrease of 24% compared to RMB 2,330,156,210.92 in Q1 2021[16]. - Tax expenses for Q1 2022 were RMB 157,142,173.60, a decrease of 43% compared to RMB 276,724,836.42 in Q1 2021[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 805,097[6]. - The number of shares held by the top ten shareholders totaled 3.67 billion shares, with Jiangsu Hengrui Medicine Group Co., Ltd. being the largest shareholder with 1.54 billion shares[8].